Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from BofA Securities

Why This Analyst Has Increased Confidence In Inovio Pharmaceuticals

Following the recent pullback in Inovio Pharmaceuticals Inc.’s (NASDAQ: INO) shares, the stock valuation seems to have been stripped of most of the remaining COVID-19 value, according to BofA Securities.

BofA Downgrades CureVac On Limited 2022 Prospects

BofA Downgrades CureVac On Limited 2022 Prospects

There is limited upside from CureVac BV’s (NASDAQ: CVAC) COVID-19 vaccine and there are few catalysts from the rest of the company’s pipeline in 2022, according to BofA Securities.

Why BofA Upgrades CH Robinson Worldwide

Why BofA Upgrades CH Robinson Worldwide

Brokerage carriers such as CH Robinson Worldwide Inc (NASDAQ: CHRW) are poised to benefit from continued strength in contract rates in the first half of 2022 and the subsequent “roll over as fluidity improves in the supply chain,” according to BofA Securities.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Why This Analyst Is Worried About Opendoor's iBuying Model In 2022

While Opendoor Technologies Inc (NASDAQ: OPEN) had strong revenues and increasing potential to gain market share, the iBuying model is “inherently risky, low margin, and capital intensive,” according to BofA Securities.

Why This Tesla Analyst Is Projecting Sharp Drop In Market Share, Benefits For Legacy Automakers

Tesla, Inc. (NASDAQ: TSLA), which has a commanding position in the U.S. electric vehicle market, could see an erosion in market share in the medium term, according to a BofA Securities analyst.

Are Netflix Shares Headed To $750?

Having fallen about 15% to kick off the year, Netflix Inc (NASDAQ: NFLX) is on pace to record its worst monthly performance since October 2018. BofA Securities analyst Nat Schindler said he remains bullish on the streaming giant.

BofA Bullish On This Gene Therapy Biotech Transitioning Into A Commercial Enterprise

Krystal Biotech Inc (NASDAQ: KRYS) shares have potential to nearly double from current levels, according to an analyst at BofA Securities.

inkl

Read news from The Economist, FT, and more,
with one subscription

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

BofA Securities

Opendoor Technologies Inc

Opendoor Technologies

CH Robinson Worldwide

Krystal Biotech

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

244,072 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play